Hepatic triglyceride biosynthesis in humans with different insulin resistance phenotypes

Recruiting

• Conditions: Dyslipidemia; insulin resistance; 10018424

• Registration Number: NL-OMON53815
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 110

Inclusion Criteria

- Ability to give informed consent; - Age 18-65y; - Overweight or class 1
obesity, defined as BMI 25-35 kg/m2; - Modest hypertriglyceridemia, defined as
fasting plasma triglycerides 1.3-3.0mM; - High risk of insulin resistance,
defined as fasting plasma insulin >64pM; - Stable weight for at least 3mo prior
to participation.

Exclusion Criteria

- Active or chronic liver disease, kidney disease, congestive heart failure,
unstable angina, history of acute cardiovascular events within 6mo of
screening, history of seizures or syncope, or an active infection requiring
antimicrobial therapy; - Use of insulin, thiazolidinediones, GLP1 agonists,
SGLT2 inhibitors, or sulfonylureas; - Use of fibrates, omega 3 (fish oil),
niacin, or PCSK9 antagonists; - Use of systemic glucocorticoids within 60d
prior to participation; - Hematocrit <35%; - Pregnancy of breastfeeding; -
Active tobacco use, excessive alcohol intake (>14U/wk), or history of drug
abuse.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Difference in %DNL between subjects with global vs muscle-only insulin<br /><br>resistance as well as the differential effects of premeal exercise on %DNL in<br /><br>these groups. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Associations between plasma markers, metabolites, and increased lipogenesis in<br /><br>humans with insulin resistance. </p><br>